Intellia Therapeutics
Trade Intellia Therapeutics 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About NTLA
Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases.
NTLA Key Statistics
Stock Snapshot
The current Intellia Therapeutics(NTLA) stock price is $9.48, with a market capitalization of 1.1B. The stock trades at a price-to-earnings (P/E) ratio of -2.39.
As of 2025-11-12, Intellia Therapeutics(NTLA) stock has fluctuated between $9.45 and $10.33. The current price stands at $9.48, placing the stock +0.3% above today's low and -8.2% off the high.
The Intellia Therapeutics(NTLA)'s current trading volume is 3.6M, compared to an average daily volume of 12.08M.
During the past year, Intellia Therapeutics(NTLA) stock moved between $5.90 at its lowest and $28.25 at its peak.
During the past year, Intellia Therapeutics(NTLA) stock moved between $5.90 at its lowest and $28.25 at its peak.
NTLA News
Intellia Therapeutics (NTLA) downgraded to a Peer Perform rating from Outperform at Wolfe Reseach, primarily due to emerging safety concerns tied to its Nex-z p...
Wolfe Research last night downgraded Intellia Therapeutics (NTLA) to Peer Perform from Outperform without a price target The safety issue for nexiguran ziclumer...
Meet Your ETF AI Analyst Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions AI Analyst can help you make smarter investment...
Analyst ratings
46%
of 26 ratingsMore NTLA News
Crispr stock jumped Monday while Intellia shares surged on promising updates for their gene-editing efforts in cholesterol treatment and a swelling disorder. A...
Intellia Therapeutics (NTLA) shares have seen a noticeable dip over the past month, continuing a trend that has lasted through much of the year. Investors are p...
Intellia Therapeutics (NTLA) presented positive clinical data from a pooled analysis of all patients who received a 50 milligram dose of lonvo-z in the company’...
On November 8, 2025, Intellia Therapeutics presented positive pooled clinical data at the ACAAI meeting, revealing that a single 50 mg intravenous dose of lonvo...
Intellia Therapeutics Inc ((NTLA)) has held its Q3 earnings call. Read on for the main highlights of the call. Meet Your ETF AI Analyst Discover how TipRanks' E...
Intellia Therapeutics (NTLA) stock crashed Friday — adding onto nearly two weeks of setbacks — after a patient in its gene-editing study died following serious...
Analyst Alec Stranahan of Bank of America Securities reiterated a Hold rating on Intellia Therapeutics, retaining the price target of $14.00. Meet Your ETF AI A...